Allergen-Specific Immunotherapy: Development & Validation of Biomarkers for Monitoring of Clinical Efficacy, Patients’ Stratification & Prognosis
Time: 5:00 pm
day: Conference Day Two - PM
Details:
- Unravelling the pathogenesis of type I IgE-mediated hypersensitivity (asthma, allergic rhinoconjunctivitis) and allergen immunotherapy treatment modalities
- Updating the current status for surrogate biomarkers of clinical efficacy endpoints and unmet needs in biomarkers of clinical response and prognosis
- Uncovering challenges in transition from analytical biomarker assay development andvalidation phase into clinical validation
